The EASL–AASLD HCC Endpoints meeting offers a platform to learn about and discuss HCC prevention, risk stratification, and local and systemic treatments. It puts a special emphasis on the impact of immune factors in carcinogenesis and treatment of HCC. It values the growing role of patient-reported outcomes on trial design and treatment decision. The HCC molecular profile is also characterised for more personalised management.
This meeting goes beyond previous meetings defining today’s and tomorrow’s practice in a rapidly changing landscape of treatment options. It is designed to not only define current state-of-the-art practice, but also to explore emerging strategies, and to suggest the way the next key trials should be designed. This intercontinental meeting also brings together the best experts to deliver accurate and didactic talks and discussions.
This meeting is a must-attend for clinicians and scientists involved in the clinical management or investigation of HCC, wanting to improve their current practice and to understand what tomorrow is going to bring.
Prevention and follow-up endpoints: This session will define current knowledge and future directions of HCC primary prevention. It will also discuss the best approach for disease monitoring after curative treatment. It includes a state-of-art lecture on how to leverage the immune system to prevent HCC development.
HCC risk stratification: This session will discuss updated approaches for risk stratification in patients at risk of HCC or after curative therapies to prevent tumour recurrence. It will explore scoring systems and the role of artificial intelligence to increase accuracy of HCC prediction.
Impact of safety profile and radiological response on patient outcomes: This session will focus on patient-reported outcomes and how they can contribute to improve clinical trial design and the evaluation of new interventions in HCC care.
Clinical trial design for liver-localised disease: This session will touch base on the increasing problem of how to better design and execute clinical trials for patients at early and intermediate stages. Issues related to endpoints on ranking levels of evidence will be discussed.
Academy-Regulatory Agency and Industry: This session will confront the different approaches for drug development from academia, industry partners, and regulatory agencies. It is key to understand how these different actors interact to bring new drugs into patient care.
Clinical trial design for systemic disease: This session will define the current knowledge on how to better design and execute clinical trials in patients at advanced stages, including the best endpoints for evaluation of response. It includes a state-of-art lecture on biomarker-driven clinical trials and how this could impact trial design in HCC in the future.